Profusa (PFSA) Non-Current Deferred Tax Liability (2022 - 2023)
Profusa's (PFSA) quarterly Non-Current Deferred Tax Liability came in at $13661.0 in Q4 2023, down 63.02% year-on-year from $36940.0 in Q4 2022, and down 98.92% quarter-over-quarter from $1.3 million in Q3 2023.
Profusa (PFSA) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Profusa's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $13661.0 for Q4 2023.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 63.02% year-over-year to $13661.0 in Q4 2023; TTM through Dec 2023 was $13661.0, a 63.02% decrease from a year earlier, with the FY2023 full-year figure at $13661.0, down 63.02% from the prior year.
- Non-Current Deferred Tax Liability eased to $13661.0 in Q4 2023 per PFSA's latest filing, from $1.3 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.3 million in Q3 2023 and bottomed at $13661.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Profusa | 23,566.40 | -351,433.60 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 13,661.00 |
| Dec 31, 2023 | 13,661.00 |
| Sep 30, 2023 | 1.27 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 735,048.00 |
| Jun 30, 2023 | 735,048.00 |
| Dec 31, 2022 | 36,940.00 |
| Dec 31, 2022 | 36,940.00 |